Skip to content
10-Q

Quarterly Report

BridgeBio Oncology Therapeutics, Inc. BBOT

0001193125-25-277834

← back to feed
Filed
Nov 12, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2025 · Nov 7, 2025 79.99M sh
Shares Diluted Q3 2025 · Sep 30, 2025 43.49M sh
Shares Diluted Q3 2025 · Sep 30, 2025 14.68M sh
Shares Diluted Q3 2025 · Sep 30, 2024 11.09K sh
Shares Diluted Q3 2025 · Sep 30, 2024 11.09K sh
Capex Q3 2025 · Sep 30, 2025 $533K
Capex Q3 2025 · Sep 30, 2024 $39K
Operating Cash Flow Q3 2025 · Sep 30, 2025 −$71.66M
Operating Cash Flow restated Q3 2025 · Sep 30, 2024 −$39.99M
Cash And Equivalents Q3 2025 · Sep 30, 2025 $408.74M
Cash And Equivalents Q3 2025 · Dec 31, 2024 $30.85M
Stockholders Equity Q3 2025 · Sep 30, 2025 $446.7M
Stockholders Equity Q3 2025 · Jun 30, 2025 −$227.73M
Stockholders Equity Q3 2025 · Mar 31, 2025 −$200.03M
Stockholders Equity Q3 2025 · Dec 31, 2024 −$178.64M
Stockholders Equity restated Q3 2025 · Sep 30, 2024 −$159.21M
Stockholders Equity restated Q3 2025 · Jun 30, 2024 −$143.44M
Stockholders Equity restated Q3 2025 · Mar 31, 2024 −$128.87M
Stockholders Equity restated Q3 2025 · Dec 31, 2023 −$115.64M
Current Liabilities Q3 2025 · Sep 30, 2025 $35.71M
Current Liabilities Q3 2025 · Dec 31, 2024 $19.58M
Total Liabilities Q3 2025 · Sep 30, 2025 $38.09M
Total Liabilities Q3 2025 · Dec 31, 2024 $19.58M
Current Assets Q3 2025 · Sep 30, 2025 $476.01M
Current Assets Q3 2025 · Dec 31, 2024 $158.69M
Total Assets Q3 2025 · Sep 30, 2025 $484.79M
Total Assets Q3 2025 · Dec 31, 2024 $164.3M
Eps Diluted Q3 2025 · Sep 30, 2025 −$1.03
Eps Diluted Q3 2025 · Sep 30, 2025 −$6.49
Eps Diluted Q3 2025 · Sep 30, 2024 −$1,562.18
Eps Diluted Q3 2025 · Sep 30, 2024 −$4,922.72
Eps Basic Q3 2025 · Sep 30, 2025 −$1.03
Eps Basic Q3 2025 · Sep 30, 2025 −$6.49
Eps Basic Q3 2025 · Sep 30, 2024 −$1,562.18
Eps Basic Q3 2025 · Sep 30, 2024 −$4,922.72
Sga Expense Q3 2025 · Sep 30, 2025 $14.13M
Sga Expense Q3 2025 · Sep 30, 2025 $19.29M
Sga Expense restated Q3 2025 · Sep 30, 2024 $1.78M
Sga Expense restated Q3 2025 · Sep 30, 2024 $5.42M
Rd Expense Q3 2025 · Sep 30, 2025 $35.05M
Rd Expense Q3 2025 · Sep 30, 2025 $83.13M
Rd Expense Q3 2025 · Sep 30, 2024 $17.89M
Rd Expense Q3 2025 · Sep 30, 2024 $53.57M
Net Income Q3 2025 · Sep 30, 2025 −$44.76M
Net Income Q3 2025 · Sep 30, 2025 −$95.25M
Net Income Q3 2025 · Jun 30, 2025 −$28.44M
Net Income Q3 2025 · Mar 31, 2025 −$22.06M
Net Income restated Q3 2025 · Sep 30, 2024 −$17.32M
Net Income restated Q3 2025 · Sep 30, 2024 −$54.59M
Net Income restated Q3 2025 · Jun 30, 2024 −$21.82M
Net Income restated Q3 2025 · Mar 31, 2024 −$15.44M
Operating Income Q3 2025 · Sep 30, 2025 −$49.18M
Operating Income Q3 2025 · Sep 30, 2025 −$102.41M
Operating Income restated Q3 2025 · Sep 30, 2024 −$19.66M
Operating Income restated Q3 2025 · Sep 30, 2024 −$58.98M